MediciNova Inc.
02/20/2026 | Press release | Distributed by Public on 02/20/2026 05:25
Unaudited Consolidated financial results for the fiscal year ended December 31, 2025 (from January 1, 2025 to December 31, 2025) (Form 8-K)
|
Unaudited Consolidated financial results for the fiscal year ended December 31, 2025 (from January 1, 2025 to December 31, 2025) |
|
(1) Consolidated operating results (Year to date) |
(Percentages indicate year-on-year changes.) |
| Net sales | Operating loss |
Loss before income taxes |
Net loss attributable to shareholders of the Company |
|||||||||||||||||||||||||||||
|
Fiscal year ended |
|
USD
(Thousands |
|
% |
|
USD
(Thousands |
|
% |
|
USD
(Thousands |
|
% |
|
USD
(Thousands |
|
% | ||||||||||||||||
|
December 31, 2025 |
409,657 | - | -13,283,002 | - | -11,991,963 | - | -11,997,957 | - | ||||||||||||||||||||||||
| (62,947 | ) | (-2,041,066 | ) | (-1,842,685 | ) | (-1,843,606 | ) | |||||||||||||||||||||||||
|
December 31, 2024 |
- | - | -12,675,331 | - | -11,044,012 | - | -11,049,549 | - | ||||||||||||||||||||||||
| (- | ) | (-1,947,691 | ) | (-1,697,022 | ) | (-1,697,873 | ) | |||||||||||||||||||||||||
| (Note) Comprehensive loss | For the fiscal year ended December 31, 2025: $11,989,983 (¥1,842,380 thousand) [-%] | |||
| For the fiscal year ended December 31, 2024: $11,066,613 (¥1,700,495 thousand [-%] |
|
Net loss per share attributable to shareholders of the Company |
Diluted net loss per share attributable to shareholders of the Company |
Return on shareholders' equity attributable to shareholders of the Company |
Ratio of income before income taxes to total assets |
Ratio of operating income to net sales |
||||||||||||||||
|
Fiscal year ended |
|
USD (JPY |
) |
|
USD (JPY |
) |
% | % | % | |||||||||||
|
December 31, 2025 |
-0.24 | - | -25.5 | % | -23.6 | % | - | |||||||||||||
| (-36 | ) | (- | ) | |||||||||||||||||
|
December 31, 2024 |
-0.23 | - | -19.2 | % | -18.1 | % | - | |||||||||||||
| (-35 | ) | (- | ) | |||||||||||||||||
(Note)
| 1. |
Net loss per share of the Company is calculated in accordance with ASC Topic 260, "Earnings Per Share." |
| 2. |
Diluted net loss per share of the Company is not presented because we incurred a net loss attributable to shareholders of the Company. |
1
| (2) |
Consolidated financial position |
| Total assets |
Total equity (Net assets) |
Shareholders' equity |
Shareholders' equity ratio |
Shareholders' equity per share |
||||||||||||||||
|
As of |
|
USD
(Thousands 45,603,109 |
|
|
USD (Thousands of JPY 41,586,681 |
) |
|
USD
(Thousands 41,586,681 |
|
% 91.2 |
|
USD (JPY 0.84 |
) |
|||||||
| (7,007,373 | ) | (6,390,209 | ) | (6,390,209 | ) | (129.07 | ) | |||||||||||||
|
December 31, 2024 |
55,875,926 | 52,503,551 | 52,503,551 | 94.0 | 1.07 | |||||||||||||||
| (8,585,894 | ) | (8,067,695 | ) | (8,067,695 | ) | (164.41 | ) | |||||||||||||
| (3) |
Consolidated cash flows |
|
Cash flows from operating activities |
Cash flows from investing activities |
Cash flows from financing activities |
Cash and cash equivalents at end of period |
|||||||||||||
|
Fiscal year ended |
|
USD
(Thousands |
|
|
USD
(Thousands |
|
|
USD
(Thousands |
|
|
USD
(Thousands |
|
||||
|
December 31, 2025 |
-9,810,061 | -2,899 | 244,018 | 30,806,477 | ||||||||||||
| (-1,507,413 | ) | (-445 | ) | (37,495 | ) | (4,733,723 | ) | |||||||||
|
December 31, 2024 |
-10,642,964 | -697 | - | 40,359,738 | ||||||||||||
| (-1,635,397 | ) | (-107 | ) | (- | ) | (6,201,677 | ) | |||||||||
(Note) The original consolidated financial statements of the Company for the fiscal years ended December 31, 2025 and December 31, 2024 are presented in US dollars. For convenience, the amounts shown in parentheses for the consolidated results of operations and consolidated financial position have been translated into Japanese yen (JPY) at a rate of JPY153.66 per USD 1.00, based on the telegraphic transfer spot exchange rate (middle rate) quoted by MUFG Bank, Ltd. as of January 30, 2026. Amounts are presented after truncating values smaller than the displayed unit.
| 2. |
Cash dividends |
| Annual dividends per share | ||||||||||||||||||||||||||||||||
|
First quarter-end |
Second quarter-end |
Third quarter-end |
Fiscal year-end |
Total |
Total cash dividends (Total) |
Payout ratio (Consolidated) |
Ratio of dividends to equity (Consolidated) |
|||||||||||||||||||||||||
|
Fiscal year ended December 31, 2025 |
|
USD (JPY) - |
|
|
USD (JPY) - |
|
|
USD (JPY) - |
|
|
USD (JPY) 0.00 |
|
|
USD (JPY) 0.00 |
|
|
USD (JPY) 0.00 |
|
|
% - |
|
|
% - |
|
||||||||
|
Fiscal year ended December 31, 2024 |
- | - | - | 0.00 | 0.00 | 0.00 | - | - | ||||||||||||||||||||||||
|
Fiscal year ending December 31, 2026 (Forecast) |
- | - | - | 0.00 | 0.00 | - | ||||||||||||||||||||||||||
| 3. |
Consolidated Forecast for the Fiscal Year Ending December 31, 2026 (January 1, 2026-December 31, 2026) |
With respect to our consolidated financial forecast for the fiscal year ending December 31, 2026, we believe that disclosing specific forecast figures for revenues and operating income could potentially hinder our ability to maximize value in connection with the strategic collaborations and out-licensing activities that we are pursuing.
In addition, if we enter into a collaboration agreement, depending on the terms and conditions of such agreement, a portion of the research and development expenses we currently expect to incur in the fiscal year ending December 31, 2026 may be borne by the counterparty. Accordingly, as it is difficult to make a reasonable forecast of our consolidated operating results, we have not provided consolidated forecast for the current fiscal year at this time.
2
| * |
Notes |
| (1) |
Significant changes in the scope of consolidation during the period: |
Newly included: companies (Company name)
Excluded: companies (Company name)
| (2) |
Changes in accounting policies |
| (i) |
Changes in accounting policies due to revisions to accounting standards and other regulations: |
| (ii) |
Changes in accounting policies due to other reasons: |
| (3) |
Number of issued shares (common stock) |
| (i) |
Total number of issued shares at the end of the period (including shares of treasury stock) |
| As of December 31, 2025 | 49,221,246 shares | |||
| As of December 31, 2024 | 49,046,246 shares |
| (ii) |
Number of shares of treasury stock at the end of the period |
|
As of December 31, 2025 |
- shares | |||
|
As of December 31, 2024 |
- shares |
| (iii) |
Average number of shares outstanding during the period |
|
For the fiscal year ended December 31, 2025 |
49,063,438 shares | |||
|
For the fiscal year ended December 31, 2024 |
49,046,246 shares |
| * |
Financial results reports are exempt from audit conducted by certified public accountants or an audit firm. |
| * |
Proper use of earnings forecasts, and other special matters |
| • |
MediciNova Inc. published this content on February 20, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on February 20, 2026 at 11:25 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]